fda update on tirzepatide Approves First Sleep Apnea Drug Tirzepatide (Mounjaro) – Advanced Care

Baseline Assessment IGF-1 serum levels Fasting glucose and HbA1c Comprehensive Metabolic Panel Cancer screening when appropriate Complete Blood Count Follow-Up Monitoring Monthly fasting glucose IGF-1 levels at 46 weeks Clinical assessment during follow-up visits Metabolic monitoring every three months Clinical Evidence Summary Several published studies support the potential applications of IGF-1 LR3 in muscle development, tissue repair, and metabolic optimization

Links to Relevant Resources References Chavda, V.P., Ajabiya, J., Teli, D., Bojarska, J., Apostolopoulos, V

Can GLP-1 Weight-Loss Drugs Increase Your Settlement Value

Diabetes 61 , 29672979 (2012)